Vivacelle Bio, Inc. Announces FDA Clearance to Enroll Patients into a Phase IIa Clinical Trial of VBI-S for Elevation of Blood Pressure in Subjects Who Have Shock Due to Sepsis

Vivacelle Bio, Inc.  announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer,  an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and efficacy of VBI-S. Vivacelle Bio, Inc. provided support for the investigational new drug application to the U.S. Food & Drug Administration for a phase IIa clinical trial of VBI-S.

READ MORE: https://blackprwire.com/press-releases/bprw-vivacelle-bio-inc-announces-fda-clearance-to-enroll-patients-into-a-phase-iia-clinical-trial-of-vbi-s-for-elevation-of-blood-pressure-in-subjects-who-have-shock-due-to-sepsis